000144451 001__ 144451
000144451 005__ 20240229112625.0
000144451 0247_ $$2doi$$a10.1186/s13148-019-0703-4
000144451 0247_ $$2pmid$$apmid:31340858
000144451 0247_ $$2pmc$$apmc:PMC6657180
000144451 0247_ $$2ISSN$$a1868-7075
000144451 0247_ $$2ISSN$$a1868-7083
000144451 0247_ $$2altmetric$$aaltmetric:65001925
000144451 037__ $$aDKFZ-2019-01903
000144451 041__ $$aeng
000144451 082__ $$a610
000144451 1001_ $$0P:(DE-He78)72d22b0cfac00f2fc21ceb7236804af0$$aJia, Min$$b0$$eFirst author$$udkfz
000144451 245__ $$aA prognostic CpG score derived from epigenome-wide profiling of tumor tissue was independently associated with colorectal cancer survival.
000144451 260__ $$a[S.l.]$$bBioMed Central$$c2019
000144451 3367_ $$2DRIVER$$aarticle
000144451 3367_ $$2DataCite$$aOutput Types/Journal article
000144451 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1568788220_3704
000144451 3367_ $$2BibTeX$$aARTICLE
000144451 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000144451 3367_ $$00$$2EndNote$$aJournal Article
000144451 520__ $$aResults of previous studies on the association of the CpG island methylator phenotype (CIMP) with colorectal cancer (CRC) prognosis were inconsistent and mostly based on different CIMP definitions. The current study aimed to comprehensively investigate the associations between DNA methylation on genes previously used to define CIMP status with CRC survival.Patients with CRC followed up for a median of 5.2 years were divided into a study cohort (n = 568) and a validation cohort (n = 308). DNA methylation was measured in tumor tissue using the Illumina Infinium HumanMethylation450 BeadChip and restricted to 43 genes used to define CIMP status in previous studies. Cox proportional hazard regression models were used to estimate adjusted hazard ratios (HR) and 95% confidence intervals (CI) of survival after CRC, including adjustment for tumor stage, microsatellite instability, and BRAF mutation status. In the study cohort, ten CpG sites were identified to be associated with CRC survival. Seven of these ten CpG sites were also associated with CRC survival in the validation cohort and were used to construct a prognostic score. CRC patients with a prognostic score of the lowest methylation level showed poorer disease-specific survival compared with patients with the highest methylation level in both the study cohort and the validation cohort (HR = 3.11 and 95% CI = 1.97-4.91, and HR = 3.06 and 95% CI = 1.71-5.45, respectively).A CpG panel consisting of seven CpG sites was found to be strongly associated with CRC survival, independent from important clinical factors and mutations associated with CIMP. Further studies are required to confirm these findings.
000144451 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000144451 588__ $$aDataset connected to CrossRef, PubMed,
000144451 7001_ $$0P:(DE-He78)6a8f87626cb610618a60d742677284cd$$aZhang, Yan$$b1$$udkfz
000144451 7001_ $$0P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aJansen, Lina$$b2$$udkfz
000144451 7001_ $$0P:(DE-He78)6c2a1ea8cce3580fe2d1c1df120a92b9$$aWalter, Viola$$b3$$udkfz
000144451 7001_ $$0P:(DE-He78)92820b4867c955a04f642707ecf35b40$$aEdelmann, Dominic$$b4$$udkfz
000144451 7001_ $$0P:(DE-HGF)0$$aGündert, Melanie$$b5
000144451 7001_ $$aTagscherer, Katrin E$$b6
000144451 7001_ $$aRoth, Wilfried$$b7
000144451 7001_ $$0P:(DE-He78)7999346780553d7fab7ba69d5afdfa71$$aBewerunge-Hudler, Melanie$$b8$$udkfz
000144451 7001_ $$aHerpel, Esther$$b9
000144451 7001_ $$aKloor, Matthias$$b10
000144451 7001_ $$aUlrich, Alexis$$b11
000144451 7001_ $$0P:(DE-He78)15b7fd2bc02d5ef47a2fe2dd0140d2bf$$aBurwinkel, Barbara$$b12$$udkfz
000144451 7001_ $$aBläker, Hendrik$$b13
000144451 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b14$$udkfz
000144451 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b15$$udkfz
000144451 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b16$$eLast author$$udkfz
000144451 773__ $$0PERI:(DE-600)2553921-8$$a10.1186/s13148-019-0703-4$$gVol. 11, no. 1, p. 109$$n1$$p109$$tClinical epigenetics$$v11$$x1868-7083$$y2019
000144451 909CO $$ooai:inrepo02.dkfz.de:144451$$pVDB
000144451 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)72d22b0cfac00f2fc21ceb7236804af0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000144451 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6a8f87626cb610618a60d742677284cd$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000144451 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000144451 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c2a1ea8cce3580fe2d1c1df120a92b9$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000144451 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92820b4867c955a04f642707ecf35b40$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000144451 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000144451 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7999346780553d7fab7ba69d5afdfa71$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000144451 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)15b7fd2bc02d5ef47a2fe2dd0140d2bf$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000144451 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000144451 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000144451 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000144451 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000144451 9141_ $$y2019
000144451 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN EPIGENETICS : 2017
000144451 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000144451 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000144451 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000144451 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000144451 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000144451 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000144451 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review
000144451 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000144451 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000144451 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000144451 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000144451 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000144451 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000144451 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCLIN EPIGENETICS : 2017
000144451 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lKlinische Epidemiologie und Alternsforschung$$x0
000144451 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x1
000144451 9201_ $$0I:(DE-He78)W110-20160331$$kW110$$lMicroarray Unit$$x2
000144451 9201_ $$0I:(DE-He78)C080-20160331$$kC080$$lMolekulare Epidemiologie$$x3
000144451 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebserkrankungen$$x4
000144451 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x5
000144451 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x6
000144451 980__ $$ajournal
000144451 980__ $$aVDB
000144451 980__ $$aI:(DE-He78)C070-20160331
000144451 980__ $$aI:(DE-He78)C060-20160331
000144451 980__ $$aI:(DE-He78)W110-20160331
000144451 980__ $$aI:(DE-He78)C080-20160331
000144451 980__ $$aI:(DE-He78)C020-20160331
000144451 980__ $$aI:(DE-He78)C120-20160331
000144451 980__ $$aI:(DE-He78)L101-20160331
000144451 980__ $$aUNRESTRICTED